The FDA's New Acting Chief Is a Food Lawyer. He Has a Supreme Court Deadline by Thursday.

Kyle Diamantas became the acting commissioner of the Food and Drug Administration on Tuesday. He has spent his FDA career in the Human Foods Program, overseeing nutrition policy, food safety, and supply-chain risk prioritization. He holds a law degree from the University of Florida, not a medical degree. He has never, in any formal regulatory capacity, overseen a drug approval decision.

By Thursday at 5 p.m. Eastern time, the Supreme Court’s short-term extension of mifepristone access through telehealth and mail-order pharmacy will expire. At that moment, the agency Diamantas now leads will need to have determined its legal posture on a case that could eliminate telehealth access to reproductive medication for millions of Americans in states with constitutionally protected abortion rights — not just in states with restrictions.

The timing is not coincidental. But the collision of an acting commissioner’s first week with one of the FDA’s most consequential pending decisions illuminates something broader about how this leadership transition was structured.

Who Kyle Diamantas Is

Diamantas’s FDA career is described in straightforward terms on the agency’s leadership page: J.D. from the University of Florida Levin College of Law, bachelor’s in political science from the University of Central Florida, private practice as a food industry lawyer before joining the FDA’s Human Foods Program. He rose to Deputy Commissioner for Food, leading the program that handles everything from nutrition labeling to infant formula safety to the federal response to Listeria contamination events.

That background is genuinely relevant to the FDA’s food mission. The Human Foods Program is real work with real public health stakes. It is not the same work as adjudicating the clinical pharmacology of prescription drug applications, setting prescribing requirements for controlled substances, or managing the agency’s response to a federal appeals court overruling its drug authorization methodology.

Marty Makary, for all the political turbulence that defined his 13-month tenure as commissioner, came to the role as a practicing surgical oncologist from Johns Hopkins. His positions on drug approvals, vaccine policy, and the mifepristone prescribing rules were sometimes at odds with career FDA scientists and with his own political principals — but they were clinically grounded. Career FDA drug review staff will now be reporting to an acting commissioner whose expertise is in supply chain safety and nutrition, not in clinical pharmacology or drug regulation.

Rolling Stone reported earlier this week that Diamantas is a hunting companion of Donald Trump Jr., which provides one data point on how a food lawyer came to be tapped as acting FDA commissioner rather than, say, the agency’s deputy commissioner for drugs, or the director of the Center for Drug Evaluation and Research. The White House has not commented on the appointment’s rationale beyond the standard announcement language.

The Mifepristone Clock

The most immediate item on Diamantas’s desk has nothing to do with food safety.

On May 1, the U.S. 5th Circuit Court of Appeals issued a ruling that effectively reinstated the FDA’s pre-pandemic mifepristone prescribing requirements — reversing the 2021 modification that allowed patients to receive the medication via telehealth consultation and mail-order pharmacy without an in-person clinic visit. The 5th Circuit ruling applies nationwide, which means it would affect patients in states with constitutional abortion access protections as much as those in states with criminal bans.

The FDA’s own stated position — made in briefs under Makary — is that the 5th Circuit decision “would upend FDA’s gold-standard, science-based drug approval system.” The agency has argued that its 2021 modification of the prescribing requirements was based on clinical evidence and that allowing courts to override FDA drug authorization methodology through litigation would set a dangerous precedent for every future drug approval the agency makes. That is not a politically charged position; it is the FDA’s institutional defense of its own statutory authority.

Justice Samuel Alito issued a short-term administrative stay blocking the 5th Circuit ruling from taking immediate effect. He then extended that stay by three days. The extension expires Thursday at 5 p.m. Eastern.

At that point, the full Court will either issue a longer-term stay — allowing telehealth mifepristone access to continue while the justices deliberate on the merits — or allow the 5th Circuit ruling to take effect, triggering immediate restrictions on how the drug can be prescribed. What FDA’s acting commissioner signals about the agency’s legal posture, and whether he maintains Makary’s position that the 5th Circuit ruling threatens FDA’s broader regulatory authority, matters for how the Court weighs the federal government’s interest in the case.

The question is not whether Diamantas personally supports or opposes mifepristone access. The question is whether he treats FDA’s defense of its 2021 prescribing modification as an institutional priority, or whether the White House’s quiet pressure — described by multiple officials as a key factor in Makary’s departure — will translate into a changed agency posture in ongoing litigation.

The Pending Drug Calendar

Beyond mifepristone, the FDA has a fixed schedule of Prescription Drug User Fee Act target action dates that do not pause for leadership transitions.

On May 18 — five days from now — the FDA is scheduled to complete its review of Daiichi Sankyo and AstraZeneca’s application for Enhertu (trastuzumab deruxtecan) in HER2-positive early breast cancer neoadjuvant treatment. On May 24, the agency faces a PDUFA date for Eisai and Biogen’s Leqembi IQLIK, a weekly-dosing formulation of the lecanemab Alzheimer’s therapy already on the market in a biweekly version.

These are not the politically charged decisions that drove Makary’s conflict with the White House. They are standard drug review completions. Career FDA reviewers in the Center for Drug Evaluation and Research have done the scientific analysis; the commissioner’s role is largely to ensure the review process ran according to statute. But they will require the acting commissioner’s signature in his first two weeks, and they will happen while the mifepristone litigation is simultaneously demanding his attention.

More politically loaded is the legacy of the vaping decisions. On May 5, the FDA under Makary authorized the first fruit-flavored electronic cigarettes for adult sale in the United States — a significant departure from the agency’s previous stance that flavor restrictions were necessary to prevent adolescent uptake of nicotine products. That decision is already made; Diamantas inherits it. What he has not yet been asked to decide is the disposition of remaining pending marketing authorization applications from other flavored vape manufacturers — a category that involves genuine regulatory judgment about the balance between adult harm reduction and youth exposure risk.

The Wider Question About This Appointment

As the opinion piece published Wednesday morning on Makary’s departure noted, the circumstances of this transition illuminate something beyond any individual’s qualifications. Makary was reportedly pushed out in part because he resisted White House pressure on mifepristone prescribing rules and on vaping authorizations — on grounds that FDA decisions must be made on scientific evidence, not political instructions. The agency’s career scientists backed that position.

The decision to replace him with the Deputy Commissioner for Food — whose portfolio is substantively separate from drug regulation — reflects a calculation that an acting commissioner with no drug regulatory record is, from the White House’s perspective, preferable to a substantive commissioner who might again exercise independent judgment on contested drug policy questions.

That calculation carries risk. The FDA’s credibility with pharmaceutical manufacturers, clinical researchers, and the global scientific community depends on its decisions being made on a predictable, evidence-based standard. A confirmed permanent commissioner with deep drug expertise and a clear relationship with the White House might be able to restore that perception of independence even under political pressure. An acting commissioner tapped from the food division, with no drug regulatory track record, creates a period of institutional uncertainty that matters particularly when the agency is simultaneously managing active litigation over its most politically sensitive drug authorization.

The district court in the mifepristone case has also set a deadline for the FDA to file a status report by October 7, 2026, detailing the agency’s progress on its safety review of the drug. Whether Diamantas initiates that review on the timeline the court expects, and whether the FDA maintains its posture defending the 2021 prescribing modification, will be among the first genuine indicators of whether his acting tenure changes the FDA’s substantive trajectory on drug policy — or is simply a placeholder while the administration identifies a permanent nominee.

By Thursday evening, at least one of those questions will have a preliminary answer.